VNA
ALIM

Valley National Advisers’s Alimera Sciences ALIM Stock Holding History

Valley National Advisers’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27
Closed – – 720
2018
Q1 		$0 Hold
27
– – ﹤0.01% 708
2017
Q4 		$1K Hold
27
– – ﹤0.01% 639
2017
Q3 		$1K Buy
+27
New +$578 ﹤0.01% 634

Other funds holding ALIM

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Valley National Advisers's ALIM Position: Q2 2018 in Review

Valley National Advisers sold out of Alimera Sciences (ALIM) in Q2 2018, closing a stake of 27 shares.

Valley National Advisers first reported a position in ALIM in Q3 2017 and held it in 3 quarters. The position peaked at $1K in Q4 2017. 37 funds tracked by Wall St. Rank hold ALIM as of Q2 2018.

  • Valley National Advisers reported no remaining Alimera Sciences position as of Q2 2018 after selling out during the quarter.
  • Valley National Advisers sold 27 Alimera Sciences shares in Q2 2018.
  • Valley National Advisers first reported a position in Alimera Sciences in Q3 2017 and held it in 3 quarters.
  • Valley National Advisers's Alimera Sciences position peaked at $1K in Q4 2017.
  • 37 funds tracked by Wall St. Rank held Alimera Sciences as of Q2 2018.

Based on Valley National Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.